Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States ; day:16 ; month:12 ; year:2023 ; pages:1-7
Endocrine ; (16.12.2023), 1-7
- Creator
-
Worden, Francis
Rajkovic-Hooley, Olivera
Reynolds, Neil
Milligan, Gary
Zhang, Jingchuan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12020-023-03638-7
- URN
-
urn:nbn:de:101:1-2024030120594194274861
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Worden, Francis
- Rajkovic-Hooley, Olivera
- Reynolds, Neil
- Milligan, Gary
- Zhang, Jingchuan
- SpringerLink (Online service)
Other Objects (12)
Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy
Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
Add-on radioiodine during long-term BRAF/MEK inhibition in patients with RAI-refractory thyroid cancers: a reasonable option?
Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
"Rai rai ra"
Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study
Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status
Treatment of Radioiodine-Induced Xerostomia in Patients with Differenciated Thyroid Carcinoma
SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy
Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
Add-on radioiodine during long-term BRAF/MEK inhibition in patients with RAI-refractory thyroid cancers: a reasonable option?
Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
"Rai rai ra"
Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study
Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status
Treatment of Radioiodine-Induced Xerostomia in Patients with Differenciated Thyroid Carcinoma
SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer
Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy
Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer
Add-on radioiodine during long-term BRAF/MEK inhibition in patients with RAI-refractory thyroid cancers: a reasonable option?
Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
"Rai rai ra"
Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study
Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status
Treatment of Radioiodine-Induced Xerostomia in Patients with Differenciated Thyroid Carcinoma